Merck, Kgaa Agreement was C4 Therapeutics’s largest revenue line in fiscal 2025, bringing in $18.48M of $35.95M (51%).
| Collaborative Arrangement and Arrangement Other than Collaborative | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Merck, Kgaa Agreement | — | — | $7.30M | $18.48M | |||
| Biogen Agreement | $19.21M | $10.62M | $16.90M | $2.00M | |||
| Calico Agreement | $6.94M | $1.07M | — | — | |||
| Roche Agreement | $4.94M | $9.06M | $3.99M | $8.80M | |||
| Merck Agreement | — | — | $3.98M | $6.02M | |||
| Betta Agreement | — | — | $3.42M | $649.00K | |||
| Total | $31.10M | $20.76M | $35.58M | $35.95M |
C4 Therapeutics brought in $35.95M from its five revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 1.0% from $35.58M in fiscal 2024. Merck, Kgaa Agreement was the largest at $18.48M (51.4%), ahead of Roche Agreement at $8.80M (24.5%) and Merck Agreement at $6.02M (16.7%). The other two revenue lines brought in $2.65M combined.
Compared with fiscal 2024, Merck, Kgaa Agreement grew fastest, up 153.0% to $18.48M, while Biogen Agreement fell the most, down 88.2% to $2.00M.
C4 Therapeutics began breaking out Merck, Kgaa Agreement in fiscal 2024, Merck Agreement in fiscal 2024 and Betta Agreement in fiscal 2024. C4 Therapeutics stopped reporting Calico Agreement as a separate revenue line after fiscal 2023, when it brought in $1.07M.
C4 Therapeutics (CCCC) reports its revenue by collaborative arrangement and arrangement other than collaborative. In fiscal 2025, Merck, Kgaa Agreement was its largest revenue line, bringing in $18.48M (51.4% of the total), followed by Roche Agreement at $8.80M (24.5%).
Merck, Kgaa Agreement was C4 Therapeutics' largest revenue line in fiscal 2025, bringing in $18.48M, or 51.4% of the $35.95M total across its five revenue lines.
Among C4 Therapeutics' revenue lines that make up at least 2% of revenue, Merck, Kgaa Agreement grew fastest in fiscal 2025, up 153.0% from $7.30M to $18.48M.
Every figure comes from C4 Therapeutics' annual financial filings, as reported. Each line keeps the name C4 Therapeutics gives it, and years follow its fiscal calendar.
C4 Therapeutics' revenue by collaborative arrangement and arrangement other than collaborative goes back to fiscal 2019, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.